LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE
Aim. To evaluate the efficacy of action of the calcium sensitizer levosimendan (LS) in patients with various grade of heart failure (HF) severity before cardiosurgery.Material and methods. LS was applied as a part of HF treatment while preparing patients for surgery in 2-4 days. Performed dose was 0...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2017-03-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1598 |
| _version_ | 1797856896127860736 |
|---|---|
| author | M. A. Babaev A. A. Eremenko O. V. Dymova P. V. Polyakova S. V. Fedulova Yu. V. Frolova |
| author_facet | M. A. Babaev A. A. Eremenko O. V. Dymova P. V. Polyakova S. V. Fedulova Yu. V. Frolova |
| author_sort | M. A. Babaev |
| collection | DOAJ |
| description | Aim. To evaluate the efficacy of action of the calcium sensitizer levosimendan (LS) in patients with various grade of heart failure (HF) severity before cardiosurgery.Material and methods. LS was applied as a part of HF treatment while preparing patients for surgery in 2-4 days. Performed dose was 0,025 — 0,1 µg/kg/min. The drug was not administered in bolus. Preoperation group of participants included 108 patients (62% — men, 38% — women, aged 20 — 72 years (53±13)) with CHF III-IV FC by NYHA, with ejection fraction of the left ventricle (LVEF) about in average 27±8%.Mean level of natriuretic B-type peptide was 1129 (Me 854, Q25 396, Q75 1419) pg/mL. Main etiology of chronic HF in participants was dilation cardiomyopathy: noncoronary cardiomyopathy in 30 patients (27,7%), ischemic cardiomyopathy (ischemic heart disease, postinfarction cardiosclerosis) in 72 patients (66,7%) and acquired valve defects in 6 patients (5,6%). For assessment of efficacy of the drug in various grade of HF severity, patients were selected to subgroups according to the level of LVEF decrease (less 20%, 21-30%, 31-40%, more 40%), and pulmonary artery pressure (PAWP) (less 40 mmHg, 40-70 mmHg, more 70 mmHg).Results. Infusion of the drug led to statistically significant increase of LVEF comparing to the baseline (57%), decrease of PAWP (64%) and BNP concentration in 77% cases. Conclusion. The LS is an effective medication which can be applied with the aims to prepare HF patients to cardiosurgical operations. Most sensitive parameters of LS efficacy are PAWP, LVEF and BNP concentration. The highest efficacy of the drug was observed in subgroup with EF ≤40%, PAWP ≥40 mmHg and BNP ≥600 pg/mL. LS, applied in HF patients before cardiosurgery, can be used for assessment of reserves of myocardial capacity. |
| first_indexed | 2024-04-09T20:49:03Z |
| format | Article |
| id | doaj.art-95e5f094818e43f5af4aab55267427cf |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:49:03Z |
| publishDate | 2017-03-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-95e5f094818e43f5af4aab55267427cf2023-03-29T21:23:27Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202017-03-0103596210.15829/1560-4071-2017-3-59-621381LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILUREM. A. Babaev0A. A. Eremenko1O. V. Dymova2P. V. Polyakova3S. V. Fedulova4Yu. V. Frolova5V. B. Petrovskiy Russian National Research Centre of SurgeryV. B. Petrovskiy Russian National Research Centre of SurgeryV. B. Petrovskiy Russian National Research Centre of SurgeryV. B. Petrovskiy Russian National Research Centre of SurgeryV. B. Petrovskiy Russian National Research Centre of SurgeryV. B. Petrovskiy Russian National Research Centre of SurgeryAim. To evaluate the efficacy of action of the calcium sensitizer levosimendan (LS) in patients with various grade of heart failure (HF) severity before cardiosurgery.Material and methods. LS was applied as a part of HF treatment while preparing patients for surgery in 2-4 days. Performed dose was 0,025 — 0,1 µg/kg/min. The drug was not administered in bolus. Preoperation group of participants included 108 patients (62% — men, 38% — women, aged 20 — 72 years (53±13)) with CHF III-IV FC by NYHA, with ejection fraction of the left ventricle (LVEF) about in average 27±8%.Mean level of natriuretic B-type peptide was 1129 (Me 854, Q25 396, Q75 1419) pg/mL. Main etiology of chronic HF in participants was dilation cardiomyopathy: noncoronary cardiomyopathy in 30 patients (27,7%), ischemic cardiomyopathy (ischemic heart disease, postinfarction cardiosclerosis) in 72 patients (66,7%) and acquired valve defects in 6 patients (5,6%). For assessment of efficacy of the drug in various grade of HF severity, patients were selected to subgroups according to the level of LVEF decrease (less 20%, 21-30%, 31-40%, more 40%), and pulmonary artery pressure (PAWP) (less 40 mmHg, 40-70 mmHg, more 70 mmHg).Results. Infusion of the drug led to statistically significant increase of LVEF comparing to the baseline (57%), decrease of PAWP (64%) and BNP concentration in 77% cases. Conclusion. The LS is an effective medication which can be applied with the aims to prepare HF patients to cardiosurgical operations. Most sensitive parameters of LS efficacy are PAWP, LVEF and BNP concentration. The highest efficacy of the drug was observed in subgroup with EF ≤40%, PAWP ≥40 mmHg and BNP ≥600 pg/mL. LS, applied in HF patients before cardiosurgery, can be used for assessment of reserves of myocardial capacity.https://russjcardiol.elpub.ru/jour/article/view/1598heart failurelevosimendanmyocardial reserveleft ventricle ejection fractionpulmonary artery pressurenatriuretic b-type peptide |
| spellingShingle | M. A. Babaev A. A. Eremenko O. V. Dymova P. V. Polyakova S. V. Fedulova Yu. V. Frolova LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE Российский кардиологический журнал heart failure levosimendan myocardial reserve left ventricle ejection fraction pulmonary artery pressure natriuretic b-type peptide |
| title | LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE |
| title_full | LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE |
| title_fullStr | LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE |
| title_full_unstemmed | LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE |
| title_short | LEVOSIMENDAN IN PREOPERATION THERAPY FOR CARDIOSURGERY IN PATIENTS WITH CHRONIC HEART FAILURE |
| title_sort | levosimendan in preoperation therapy for cardiosurgery in patients with chronic heart failure |
| topic | heart failure levosimendan myocardial reserve left ventricle ejection fraction pulmonary artery pressure natriuretic b-type peptide |
| url | https://russjcardiol.elpub.ru/jour/article/view/1598 |
| work_keys_str_mv | AT mababaev levosimendaninpreoperationtherapyforcardiosurgeryinpatientswithchronicheartfailure AT aaeremenko levosimendaninpreoperationtherapyforcardiosurgeryinpatientswithchronicheartfailure AT ovdymova levosimendaninpreoperationtherapyforcardiosurgeryinpatientswithchronicheartfailure AT pvpolyakova levosimendaninpreoperationtherapyforcardiosurgeryinpatientswithchronicheartfailure AT svfedulova levosimendaninpreoperationtherapyforcardiosurgeryinpatientswithchronicheartfailure AT yuvfrolova levosimendaninpreoperationtherapyforcardiosurgeryinpatientswithchronicheartfailure |